Business Context and Reporting Period
This Form 8-K is a current report filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc.) on April 27, 2018. The filing details the entry into a material definitive agreement for a public offering of securities and amendments to the company's capital structure. The company is an emerging growth company focused on clinical and preclinical development programs.
Key Financial Metrics and Capital Structure
The filing does not provide historical revenue, profit, cash flow, or margin data. The primary financial activity reported is a capital raise:
- Offering Size: 46,588,234 shares of Common Stock, 12,235,295 Pre-Funded Warrants, and Preferred Stock Warrants to purchase up to 1,470,588.225 shares of Series B Convertible Preferred Stock.
- Offering Price: $0.425 per Common Stock unit and $0.415 per Pre-Funded Warrant unit (each sold with a Preferred Stock Warrant).
- Expected Net Proceeds: Approximately $22.2 million from the primary offering.
- Over-Allotment Option: The underwriter, H.C. Wainwright & Co., LLC, fully exercised an option for 8,823,529 additional shares and related warrants, generating an additional expected net proceeds of approximately $3.4 million.
- Use of Proceeds: Funding clinical and preclinical programs, research and development, capital expenditures, and working capital.
- Underwriting Costs: 8.0% commission plus 1.0% management fee on gross proceeds.
Material Changes and Corporate Actions
The filing reports several material changes to the company's securities and agreements:
- Series B Preferred Stock: The company filed a Certificate of Designation for Series B Convertible Preferred Stock. Each 0.025 share converts into one share of Common Stock. Conversion is contingent upon a Charter Amendment to increase authorized shares, which requires stockholder approval.
- Lock-Up Waiver and Repricing: To facilitate the offering, the company obtained a waiver of a 135-day lock-up agreement from a February 2018 offering. In exchange, the exercise price of February 2018 Preferred Stock Warrants was repriced from $1.01 to $0.44625 per 0.1 share of Series A Convertible Preferred Stock.
- Lock-Up Period: The company agreed to a 120-day lock-up period following the offering, prohibiting the sale of additional Common Stock or convertible securities without underwriter consent.
Guidance, Risks, and Contingencies
Management commentary is limited to the intended use of proceeds and the expectation that the offering will close on or about May 1, 2018. The filing includes significant forward-looking statements and risks:
- Financing Risk: The company explicitly notes the need for additional financing and the potential to scale back operations if adequate financing is not obtained.
- Regulatory and Clinical Risk: Success depends on the timing of clinical trials and regulatory approvals.
- Contingency: The conversion of Series B Preferred Stock is contingent on stockholder approval of a Charter Amendment to increase authorized shares. The company intends to seek this approval within 45 days of the prospectus date.
- Ownership Limits: Holders are prohibited from converting Series B Preferred Stock if it would result in ownership exceeding 4.99% (or 9.99% in certain circumstances) of outstanding common stock.
Investor Verification Checklist
- Verify the closing date of the offering (expected May 1, 2018) and the actual net proceeds received.
- Confirm whether stockholders approved the Charter Amendment required to authorize the conversion of Series B Preferred Stock.
- Review the impact of the repriced February 2018 Preferred Stock Warrants on existing shareholder dilution.
- Monitor the company's cash runway and any announcements regarding the need for further capital raises.
- Check for updates on the status of clinical trials and regulatory filings mentioned in the risk factors.